REPORTS FROM YEREVAN STATE UNIVERSITY ADD NEW DATA TO RESEARCH IN MITOMYCIN THERAPY
Biotech Week
April 14, 2010
Research findings, ‘Proline-rich polypeptide-1 protects the cells
in vitro from genotoxic effects of mitomycin C,’ are discussed in
a new report. According to recent research from Yerevan, Armenia,
"A new proline-rich polypeptide (PRP-1) has been earlier shown to
possess a broad spectrum of biological activities and seems to be a
potential medicine. The potential genotoxic properties of PRP-1 and
protective effect of PRP-1 against genotoxic action of Mitomycin C
(MMC) were analyzed in details in the present work."
"DNA and chromosome damages were studied in KCL-22 cell line of human
myeloid leukemia by the Comet assay and micronucleus induction test,
respectively. The results suggest that DNA damages are, at least
partly, transient and reparable. PRP-1 at the doses 0.5-2.0 microg/ml
does not possess genotoxic activity. Moreover, this peptide expresses
both preventive and therapeutic effects against MMC-induced DNA
damage. Pre-treatment of cells with PRP-1 also prevents the appearance
of daughter cells bearing as heavy MMC-induced DNA/chromosome damages
as MNs. Thus, the polypeptide studied is able to protect the cells
from genotoxic action of MMC. This defense includes not only DNA but
also heritable chromosome damage in post-mitotic cells," wrote R.M.
Aroutiounian and colleagues, Yerevan State University (see also
Mitomycin Therapy).
The researchers concluded: "Possible mechanisms of PRP-1 protective
action are discussed."
Aroutiounian and colleagues published their study in Neurochemical
Research (Proline-rich polypeptide-1 protects the cells in vitro
from genotoxic effects of mitomycin C. Neurochemical Research,
2010;35(4):598-602).
For additional information, contact R.M. Aroutiounian, Yerevan State
University, Yerevan, Armenia.
Publisher contact information for the journal Neurochemical Research
is: Springer, 233 Spring Street, New York, NY 10013, USA.